MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 Asset Class: Stock

Company 2024/04/23 17:35:30 45.00 **Price** 40.00 19.00 **EUR** 35.00 **Difference** 0.00%(0.00) 30.00 25.00 **Contact Details** 20.00 MARINOMED BIOTECH AG Tel: +43-1-2262-90300 Fax: +43-1-25077-4493 15.00 05.2023 07.2023 09.2023 11.2023 01.2024 03.2024 Web: http://www.marinomed.com

Hovengasse 25

2100 Korneuburg E-mail: -

Company Profile

Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the following segments: Immunology, Virology, and Other. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	7,135,000		14,267,000		12,877,000	
Common stock capital		1,523,000		1,506,000		1,480,000
Fixed assets	7,476,000		8,019,000		8,459,000	
Equity capital of a company		-10,136,000		-4,157,000		191,000
Cash and cash equivalents	2,588,000		8,175,000		5,802,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		9,653,000		5,956,000		6,013,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		15,094,000		20,487,000		15,131,000
Different income		-		-		-
Other liabilities		254,000		304,000		87,000
Total assets	14,611,000	14,611,000	22,286,000	22,286,000	21,337,000	21,337,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	52	49	47
Equity ratio	-69.37%	-18.65%	0.90%
Debt-equity ratio	-244.15%	-636.11%	11,047.86%

Others

	2023	2022	2021
Tax Expense Rate	-0.06%	-0.11%	-3.46%

MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 WKN: - Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	9,183,000	11,275,000	11,627,000
Net income	-6,794,000	-6,397,000	-5,891,000
EBIT	-4,317,800	-3,882,900	-4,185,100
Operating income before taxes	-6,790,000	-6,390,000	-5,694,000
Cash Flow	-4,528,000	-5,202,000	-4,866,000
Net interest income	-2,473,000	-2,508,000	-1,509,000
Research and development expenses	7,032,000	6,905,000	7,504,000
Income taxes	4,000	6,000	197,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	176,606	230,120	247,400

Board of Directors	
Simon Nebel	Chairman of Supervisory Board
Elisabeth Lackner	Member of Supervisory Board
Eva Hofstädter-Thalmann	Member of Supervisory Board
Brigitte Ederer	Member of Supervisory Board
Ulrich Kinzel	Member of Supervisory Board

Members of Management Board			
Chairman of Managing Board			
Member of Executive Committee			
Member of Executive Committee			
	Chairman of Managing Board Member of Executive Committee		